***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: OBJECTIVE To evaluate the difference of efficacy , side-effects and quality of life in advanced non-small-cell lung cancer ( NSCLC ) patients treated with oxaliplatin plus vinorelbine or cisplatin plus vinorelbine .  METHODS Eligible patients were r and omly assigned to NL  ( oxaliplatin + vinorelbine ) group and NP ( cisplatin + vinorelbine ) group in a 2:1 ratio . In the NL group , 70 evaluable cases were treated with oxaliplatin 130 mg/m(2 ) i.v . on day 2 , and vinorelbine 25 mg/m(2 ) i.v . on days 1 and 8 in 21 days per cycle . In the NP group , 32 evaluable cases were treated with cisplatin 80 mg/m(2 ) i.v . divided to 2 - 3 days dosing , 21 days per cycle , and vinorelbine administered by the same way as in the NL group . The response rate , time to progression ( TTP ) , one-year survival , side-effects and the quality of life were observed . RESULTS The response rate was 35.7 % vs. 43.8 % ( P = 0.4 ) , median TTP was 4.7 months vs. 5.5 months ( P = 0.6 ) , one-year survival rate was 38.5 % vs. 58.6 % ( P = 0.07 ) in the NL and NP groups , respectively . Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group ( 68.4 % vs. 36.4 % , P = 0.0017 ) . However , Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group ( 49.4 % vs. 70.6 % , P = 0.037 ) . There was no statistically difference between the two groups regarding quality of life . CONCLUSION Due to good efficacy and tolerability , the NL regimen offered a new c and i date for treating advanced NSCLC BACKGROUND Vinorelbine ( NVB ) and oxaliplatin ( OXA ) have shown effective anticancer activity in a wide range of solid tumors . This study is to observe the efficacy and side effects of OXA in combination with NVB in the treatment of advanced non-small cell lung cancer ( NSCLC ) . METHODS Fifty-nine patients with NSCLC were r and omly treated by OXA+NVB or cisplatin (DDP)+NVB regimen , repeated every 3 - 4 weeks . They received at least 2 cycles of chemotherapy . RESULTS There were 29 patients treated with NO regimen , in which there was no complete response ( CR ) patient , 12 patients showed partial response ( PR ) , and the response rate was 41.4 % . There were 30 patients treated with NP regimen . One patient showed CR , 13 patients showed PR , and the response rate was 46.7 % . There was no significant difference in response rate between the two groups ( P > 0.05 ) . The major toxicities , including leukopenia and phlebitis , were similar in the two groups . The incidences of gastrointestinal reaction and alopecia of NP regimen were more severe than those of NO regimen ( P < 0.05 ) , but neurotoxicity of NO regimen was more obvious than that of NP regimen ( P < 0.05 ) . CONCLUSIONS The efficacy of the two regimens are similar in the treatment of advanced NSCLC . The side effects such as leukopenia and phlebitis are similar in the two groups . However , there are significant differences in gastrointestinal reaction , alopecia and neurotoxicity between the two groups . All the toxicities are well tolerable BACKGROUND & OBJECTIVE Oxaliplatin ( LOHP ) is an effective drug in treatment of non-small cell lung cancer ( NSCLC ) with mild toxicities to gastrointestinal tract , kidney , and bone marrow . Cisplatin ( DDP ) plus vinorelbine ( NVB ) constitute the first-line regimen ( NP regimen ) for NSCLC . This study was to compare the short-term response , long-term outcome , and adverse events between advanced NSCLC patients received NO regimen ( LOHP plus NVB ) and NP  regimen . METHODS A total of 90 patients with advanced NSCLC were r and omized into NO group ( 58 patients , 25 mg/m(2 ) of NVB , day 1 and day 8 ; 130 mg/m(2 ) of LOHP , day 1 ) and NP group ( 32 patients , 25 mg/m(2 ) of NVB , day 1 and day 8 ; 50 mg/m(2 ) of DDP , day 2 and day 3 ) . The short-term response , long-term outcome , adverse events , and survival status of the 2 groups were observed . RESULTS The response rates were 33.33 % in NO group , and 35.48 % in NP group , but no significant difference was detected between the 2 groups ( P > 0.05 ) . The clinical benefit response rate was significantly higher in NO group than in NP group ( 80.70 % vs. 64.52 % , P < 0.05 ) . The median time to progression ( TTP ) was 17 weeks in NO group , and 15 weeks in NP group ; the median time of remission was 21 weeks in NO group , and 19 weeks in NP group ; the median survival time was 39 weeks in NO group , and 37 weeks in NP group ; the 1-year survival rate was 37.93 % in NO group , and 31.25 % in NP group . No significant differences were detected between the 2 groups . The incidence rates of phlebitis and grade I-II peripheral neuritis were significantly higher in NO group than in NP group ( 77.59 % vs. 50.00 % , P<0.01 ; 43.10 % vs. 15.63 % , P<0.01 ) . The incidence rate of grade III-IV nausea/vomiting was significantly higher in NP group than in NO group ( 31.25 % vs. 3.45 % , P<0.05 ) . CONCLUSIONS The efficacy of NO regimen on advanced NSCLC is similar to that of NP regimen , but the clinical benefit response rate is higher in NO group than in NP group . In short , NO regimen may be recommended as the first-line chemotherapy regimen for advanced NSCLC PURPOSE To evaluate the activity and tolerance of gemcitabine in combination with oxaliplatin ( GEMOX regimen ) in pretreated patients with advanced non-small cell lung cancer ( NSCLC ) . PATIENTS AND METHODS Thirty-two patients with advanced NSCLC who had disease progression after a cisplatin- and taxane-based front-line regimen were treated with gemcitabine ( 1500 mg/m(2 ) on days 1 and 8) and oxaliplatin ( 130 mg/m(2 ) on day 8) every 3 weeks . The patients ' median age was 62 years and the performance status ( WHO ) was 0 for 11 , 1 for 17 and 2 for 4 patients . The treatment was second line for 22 ( 69 % ) and > or = third line for 10 ( 31 % ) patients . RESULTS Partial response was achieved in 5 ( 16 % ) patients , stable disease in 8 ( 25 % ) and progressive disease in 19 ( 59 % ) . Two patients with stable disease and one patient with progressive disease while on previous chemotherapy experienced a partial response with GEMOX regimen . The median duration of response was 2.5 months ( range , 1 - 11.5 ) , the median time to tumor progression 3 months ( range , 1 - 18 ) and the median survival 5.6 months ( range , 1 - 31 ) . Grade III neutropenia occurred in five ( 16 % ) patients , grade III thrombocytopenia in two ( 6 % ) and grade III anemia in three ( 9 % ) ; moreover , grade s II-III asthenia was reported in eight ( 25 % ) patients and grade s II-III neurotoxicity in three ( 9 % ) . CONCLUSION The GEMOX combination is a relatively active and well tolerated second-line regimen in NSCLC patients pretreated with a taxane- and /or platinum-based chemotherapy Introduction : We conducted a multicenter phase II study to evaluate the efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in patients with advanced non-small cell lung cancer ( NSCLC ) . Methods : Patients with chemotherapy-naive , nonsquamous , stage IIIB or IV NSCLC received gemcitabine 1000 mg/m2 on days 1 and 8 , oxaliplatin 130 mg/m2 on day 1 , and bevacizumab 15 mg/kg on day 1 every 21 days for 4 cycles . Patients with stable disease or response received maintenance bevacizumab every 3 weeks until progression . Primary end point was median time to progression ( TTP ) . Results : Nineteen of 44 eligible patients had partial response in the intent-to-treat analysis for an objective response rate of 43 % ( 95 % confidence interval [ CI ] , 26.3–60.1 % ) ; 16 patients had stable disease for a disease control rate of 80 % ( 95 % CI , 72.0–87.0 % ) . Median TTP was 5.5 months ( 95 % CI , 3.8–6.9 months ) , which approached that seen in phase III studies . Median survival was 13.7 months ( 95 % CI , 7.3–21.8 months ) . The most common grade 3 or 4 adverse events were hypertension ( 11 % ) , neutropenia ( 9 % ) , diarrhea ( 7 % ) , dyspnea ( 7 % ) , and thromboembolic events ( 7 % ) . Pulmonary hemorrhage was not observed . Conclusions : The results of this phase II study suggest that oxaliplatin and gemcitabine with bevacizumab was active and reasonably well tolerated . Median TTP approached that in phase III studies . This combination represents another treatment option for advanced NSCLC PURPOSE We design ed a prospect i ve r and omized trial to compare vinorelbine and cisplatin ( NVB-P ) with vindesine and cisplatin ( VDS-P ) and to evaluate whether the best of these regimens affords a survival benefit compared with vinorelbine alone ( NVB ) , an outpatient regimen , in patients with non-small-cell lung cancer ( NSCLC ) . PATIENTS AND METHODS Forty-five centers included 612 patients in this study : 206 on NVB-P , 200 on VDS-P , and 206 on NVB . Vinorelbine was administered at a dose of 30 mg/m2 weekly , cisplatin at 120 mg/m2 on days 1 and 29 and then every 6 weeks , and vindesine at 3 mg/m2 weekly for 6 weeks and then every other week . Treatment was continued until progression or toxicity . Four percent of the patients entered were ineligible and 59 % had metastatic disease . RESULTS An objective response rate was observed in 30 % of patients in the NVB-P arm versus 19 % in the VDS-P arm ( P = .02 ) and 14 % in the NVB arm ( P < .001 ) . The median duration of survival was 40 weeks in the NVB-P arm , compared with 32 weeks in the VDS-P arm and 31 weeks in the NVB arm . Comparison of survival among the three groups demonstrated an advantage for NVB-P compared with VDS-P ( P = .04 ) and NVB ( P = .01 ) . Neutropenia was significantly higher in the NVB-P group ( P < .001 ) , and neurotoxicity was more frequent with VDS-P ( P < .004 ) . CONCLUSION Since our results have demonstrated that NVB-P yields a longer survival duration and a higher response rate than VDS-P or NVB alone , with acceptable toxicity , this combination should be considered a relevant regimen in advanced NSCLC Lung cancer is the leading cause of cancer death in the world , causing more than one million deaths each year . The incidence and mortality rates are highest in the United States and Europe and continue to increase in developing nations . Non-small cell lung cancer ( NSCLC ) accounts for 80 to 85 % of all new cases of lung cancer . The majority of patients with NSCLC present with advanced disease at the time of diagnosis . Although the prognosis of advanced NSCLC is very poor , current chemotherapy combinations have been shown to improve 1-year survival and quality of life for these patients . Approximately one third of patients with NSCLC are diagnosed with locally advanced disease . Although cure rates are modest and variable in locally advanced NSCLC , multimodality therapy ( chemotherapy in combination with surgery or radiotherapy ) has result ed in statistically significant improvement in 5-year survival when compared with surgery or radiotherapy alone . Patients with early-stage NSCLC have the best long-term survival rates following surgical resection ; however , systemic recurrences remain a problem in the majority of these patients . The rationale for treating patients with early-stage NSCLC with combined-modality therapy ( chemotherapy and surgery ) is compelling , and several r and omized trials are currently in progress . Although progress has been slow , when we consider the recent advances in smoking prevention , smoking cessation , staging classification , imaging and diagnostic techniques , screening and therapeutic modalities , and multidisciplinary care , as well as in the under 
    Output:
    
There were no statistical differences between NO and NP in overall response rate , disease control rate , 1-year survival rate , anemia and thrombocytopenia .
Gastrointestinal toxicity , leucopenia , alopecia and kidney toxicity were more serious in NP ( P < 0.05 ) , but neuritis was more serious in NO , with significant difference ( P < 0.05 ) .
The clinical efficacy of NO and NP for advanced NSCLC was similar , but the side effects were different .
The toxicity of NO has the tendency to be more tolerable